Literature DB >> 7490604

Do antidepressants cause, promote, or inhibit cancers?

A B Steingart1, M Cotterchio.   

Abstract

UNLABELLED: Do antidepressants cause, promote, or inhibit cancers?
OBJECTIVE: To review all human and experimental studies that examined the association of antidepressants with cancer or the effect of antidepressants on neoplastic growth.
METHODS: A search was conducted of MEDLINE for relevant articles published in English between 1976 and 1993.
RESULTS: Four human studies and nine experimental models were found. The human studies showed a transiently statistically significant positive association between amitriptyline and liver cancer and a negative association with pancreatic cancer; and that the antidepressants amitriptyline, nortriptyline, desipramine, and phenelzine may increase risk of breast cancer. Results of the experimental studies differed depending on which antidepressants were examined and which model was used. Amitriptyline was found to promote tumour growth, fluoxetine and clomipramine were reported to be both tumour promoters and antineoplastic agents, and imipramine and citalopram both demonstrated antineoplastic properties.
CONCLUSIONS: Further epidemiologic studies in humans are needed to determine which antidepressants cause, promote, or inhibit cancers.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7490604     DOI: 10.1016/0895-4356(95)00545-5

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  21 in total

Review 1.  Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened.

Authors:  Gary D Friedman; Natalia Udaltsova; James Chan; Charles P Quesenberry; Laurel A Habel
Journal:  Cancer Causes Control       Date:  2009-12       Impact factor: 2.506

2.  Quality of reviews in epidemiology.

Authors:  R A Breslow; S A Ross; D L Weed
Journal:  Am J Public Health       Date:  1998-03       Impact factor: 9.308

Review 3.  Depression and glioblastoma, complicated concomitant diseases: a systemic review of published literature.

Authors:  Luke Mugge; Tarek R Mansour; Megan Crippen; Yasaman Alam; Jason Schroeder
Journal:  Neurosurg Rev       Date:  2018-08-09       Impact factor: 3.042

4.  Association between antidepressant medication use and epithelial ovarian cancer risk: a systematic review and meta-analysis of observational studies.

Authors:  Yun-Long Huo; Jia-Ming Qiao; Song Gao
Journal:  Br J Clin Pharmacol       Date:  2018-02-05       Impact factor: 4.335

5.  Fluoxetine synergys with anticancer drugs to overcome multidrug resistance in breast cancer cells.

Authors:  Ting Zhou; Jingjing Duan; Yan Wang; Xin Chen; Ganping Zhou; Rongkan Wang; Liwu Fu; Feng Xu
Journal:  Tumour Biol       Date:  2012-05-02

Review 6.  Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers' financial associations with industry.

Authors:  Lisa Cosgrove; Ling Shi; David E Creasey; Maria Anaya-McKivergan; Jessica A Myers; Krista F Huybrechts
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

7.  Psychological aspect of cancer: From stressor to cancer progression.

Authors:  Aihua Yuan; Shukui Wang; Zongfang Li; Chen Huang
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

8.  Breast cancer recurrence risk in relation to antidepressant use after diagnosis.

Authors:  Jessica Chubak; Diana S M Buist; Denise M Boudreau; Mary Anne Rossing; Thomas Lumley; Noel S Weiss
Journal:  Breast Cancer Res Treat       Date:  2007-12-06       Impact factor: 4.872

9.  Antidepressant use and colorectal cancer risk: a Danish population-based case-control study.

Authors:  D P Cronin-Fenton; A H Riis; T L Lash; S O Dalton; S Friis; D Robertson; H T Sørensen
Journal:  Br J Cancer       Date:  2010-09-28       Impact factor: 7.640

10.  The effects of tricyclic antidepressants on breast cancer risk.

Authors:  C R Sharpe; J-P Collet; E Belzile; J A Hanley; J-F Boivin
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.